NEW HAVEN, Conn., Oct. 11 /PRNewswire/ -- VaxInnate Corporation, today announced that it has received a Contract from the Department of Health and Human Services for the Study of Innate Immune Receptors and Adjuvant Discovery.
Recent evidence demonstrates that fusing a polypeptide ligand specific for a toll-like receptor (TLR) to an antigen of interest generates a vaccine that is more potent and selective than the antigen alone. VaxInnate is working on further developing the biopanning approach for high-throughput screening (HTS), which will offer a rapid and cost effective way to discover and optimize new TLR ligands, and incorporate those ligands into vaccines for use against infectious diseases that pose a public health and national defense threat. VaxInnate has also received a Grant from the Department of Health and Human Services for the Discovery of Novel TLR Ligands with Adjuvant Properties.
The goal of the program is to identify, characterize, and express polypeptide ligands for known TLR (toll-like receptors), and use the ligands as tools to develop a better understanding of the immunological sequelae associated with triggering each TLR. Such studies could lead to a new generation of very efficacious and cost-effective vaccines.
VaxInnate Corporation is a private biotechnology company focused on exploiting the principles of innate immunity to provide an entirely new technology platform for the development and commercialization of next generation prophylactic vaccines and immune therapies. The Company's VaxIne(a) technology is a proprietary type of vaccine that contains an antigen coupled with Pathogen-Associated Molecular Patterns (PAMPs). For more information on VaxInnate, please visit http://www.vaxinnate.com/.
Except for historical facts, the statements in this news release, as well as oral statements or other written statements made or to be made by VaxInnate Corporation, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. For example, statements about the Company's ability to formulate drug products, its operations and ability to manage its growth, the expected effects of the Company's expansion of its production facilities, the availability of sufficient capital, research and development efforts and the Company's ability to file for and obtain U.S. Food and Drug Administration approvals for future products, are forward-looking statements. Forward- looking statements are merely the Company's current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. For a description of additional risks, and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments.
Company Contact: VaxInnate Corporation Carlo Russo, President & CEO (203) 785-1161 Investor Contacts: Investor Relations Phone: (609) 860-5590 andreea.cordoba@vaxinnate.com
VaxInnate CorporationCONTACT: Carlo Russo, President & CEO of VaxInnate Corporation, +1-203-785-1161, or Investor Relations, +1-609-860-5590,andreea.cordoba@vaxinnate.com
Web site: http://www.vaxinnate.com/